151751-Najiba-Chargi

270 CHAPTER 14 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer sta - tistics 2018: GLOBOCAN estimates of in - cidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68(6):394-424. doi:10.3322/caac.21492 2. Grégoire V, Lefebvre J-L, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2010;21:v184-v186. doi:10.1093/annonc/mdq185 3. Beijer YJ, Koopman M, Terhaard CHJ, Brau - nius WW, Van Es RJJ, De Graeff A. Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: Our experience in one hundred and twenty-five patients. Clin Otolaryngol . 2013;38(1):69-74. doi:10.1111/coa.12002 4. Al-Mamgani A, de Ridder M, Navran A, Klop WM, de Boer JP, Tesselaar ME. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. Eur Arch Oto-Rhino-Laryngolo- gy . 2017;274(10):3757-3765. doi:10.1007/ s00405-017-4687-4 5. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-posi- tive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet . 2019;393(10166):51-60. doi:10.1016/S0140-6736(18)32752-1 6. Rier HN, Jager A, Sleijfer S, Maier AB, Levin M. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist . 2016;21(11):1396-1409. doi:10.1634/theon - cologist.2016-0066 7. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. 2017. doi:10.1016/j.oraloncol - ogy.2017.05.012 8. Sjøblom B, Benth JŠ, Grønberg BH, et al. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity FromCarbo - platin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Clin Lung Cancer . 2017;18(2):e129-e136. doi:10.1016/j. cllc.2016.09.008 9. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sar- copenic obesity in patients with solid tu- mours of the respiratory and gastrointesti- nal tracts: a population-based study. Lancet Oncol . 2008;9(7):629-635. doi:10.1016/ S1470-2045(08)70153-0 10. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett . 2015;237(3):219- 227. doi:10.1016/j.toxlet.2015.06.012 11. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur J Cancer . 2002;38(13):1677-1684. doi:10.1016/ S0959-8049(02)00151-X 12. Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat ‐ Fixed Dosing Versus Body Surface Area–Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference? Oncolo- gist . 2007;12(8):913-923. doi:10.1634/the - oncologist.12-8-913 13. De Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol . 2001. doi:10.1200/ JCO.2001.19.17.3733